Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30254317 | 0.79 | SMN1; SMN2 (0.43) | PDK1PDK2PDK3PDK4CA2 | |
| SCHEMBL23885689 | 0.79 | SMN1; SMN2 (0.43) | PDK1PDK2PDK3PDK4CA2 | |
| SCHEMBL30254529 | 0.79 | CA2 (0.39) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL23885406 | 0.79 | CA2 (0.39) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL3220102 | 0.77 | CA2 (0.38) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL23885291 | 0.76 | CA2 (0.41) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL30254414 | 0.76 | CA2 (0.41) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL31263190 | 0.76 | SMN1; SMN2 (0.37) | PDK1PDK2PDK3PDK4CA2 | |
| SCHEMBL3226137 | 0.75 | CYP1A2 (0.42) | PDK1PDK2PDK3PDK4SMN1; SMN2 | |
| SCHEMBL2077257 | 0.68 | SLC40A1 (0.49) | PDK1PDK2PDK3PDK4SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| CN-102112476-A | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM INT | 2011-06-29 | — | — | CN | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | PDK1 2724/4885PDK2 3048/4885PDK3 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.